James E. Langston’s practice focuses on public and private merger and acquisition transactions.
Jim also provides advice regarding governance matters and the fiduciary duties of officers and directors to companies and their boards.
In 2016, Law360 named Jim one of its “Rising Stars” for his work on some of the largest and most high-profile M&A transactions in recent years. Jim was also named a “Next Generation Lawyer” for Private Equity Buyouts by Legal 500 U.S.
Jim joined the firm in 2011 and became a partner in 2015.
Public Company Transactions
General Mills in its pending $8 billion acquisition of Blue Buffalo Pet Products.
Songa Offshore in its pending $3.8 billion combination with Transocean.
Allergan in its:
- $160 billion announced merger with Pfizer
- $40.5 billion sale of its global generics pharmaceuticals business to Teva
- $2.1 billion acquisition of Kythera Biopharmaceuticals
Suntory Holdings in its $16 billion acquisition of Beam.
Medtronic in its $49.9 billion acquisition of Covidien.
Biomet and its private equity consortium owners — Blackstone, Goldman Sachs PIA, KKR and TPG — in Biomet’s $13.35 billion cash and stock merger with Zimmer Holdings.
Surgical Care Affiliates in its $2.5 billion sale to United Health Group.
Lafarge in various divestitures in connection with its €40 billion merger of equals with Holcim.
Acadia Healthcare Company in its $1.2 billion acquisition of CRC Health Group.
Conversus Capital in its $1.4 billion sale to an affiliate of HarbourVest Partners.
Duravant in its $176 million tender offer to acquire Key Technology.
Hostile M&A Transactions, Shareholder Activism & Conflict Transactions
Akamai Technologies in its negotiated settlement with Elliott Management.
Actavis in its $70 billion white knight acquisition of Allergan.
Special Committee of the Board of Directors of Spectrum Brands in the pending $10 billion combination of Spectrum Brands and HRG Group (the 58% stockholder of Spectrum).
Westlake Chemical Corporation in its unsolicited proposal to acquire Axiall Corporation and related proxy contest and the resulting $3.8 billion negotiated acquisition.
GlaxoSmithKline in its unsolicited tender offer to acquire Human Genome Sciences and the resulting $3.6 billion negotiated acquisition.
Danfoss A/S in its tender offer to acquire the outstanding shares of Sauer-Danfoss not already owned by Danfoss.
Private Equity M&A Transactions
TPG Capital in numerous transactions, including its:
- $2.25 billion acquisition of RCN Telecommunications and Grande Communications
- investment in Creative Artists Agency
- recapitalization of RentPath, including the sale of a significant equity stake to Providence Equity Partners
- $1.7 billion acquisition of Savers
- $525 million take-private acquisition of PRIMEDIA
Warburg Pincus in numerous matters, including its acquisitions of:
- Universal Services of America and Guardsmark
- Wencor Group
- Gabriel Brothers
Bausch + Lomb and Warburg Pincus in the $8.7 billion sale of Bausch + Lomb to Valeant Pharmaceuticals.
Neiman Marcus, TPG Capital and Warburg Pincus in the $6 billion sale of Neiman Marcus to Ares Management and CPPIB.
Other Corporate Transactions
RCN Communications in its $2.3 billion acquisition of Wave Broadband.
GT Nexus in its $675 million acquisition by Infor.
Biomet in its acquisition of the global trauma business of DePuy Orthopaedics.
Universal Services of America in numerous matters, including its:
- merger of equals transaction with Allied Barton
- $131 million acquisition of the security business of ABM Industries
Financial Advisor Assignments
Goldman Sachs, Barclays, Morgan Stanley, Lazard, Bank of America Merrill Lynch, J.P. Morgan, and Citigroup as financial advisor in numerous transactions.
Assessing Financial Advisor Compensation Disclosure Following Vento v. Curry, Cleary M&A and Corporate Governance Watch Blog (April 10, 2017)
March 28, 2018
November 28, 2017
April 17, 2017
January 29, 2016